Antibody Drug Conjugates (ADC) molecules utilize specific antibodies to deliver therapeutic small molecules specifically to cancer cells. ADC are created in cooperation with Bai-Li Pharmaceutical’s R&D Center of Excellence and enable the development of sophisticated chemistries that give this class of drugs their therapeutic payload. This advanced functional class is referred to as Heterogeneity overcoming - Immunogenic death inducing - Resistance antagonizing - Enhanced Specificity (HIRE) molecules that target cancer cells. 

The ADC BL-M11D1 is a CD33 specific antibody based on the drug Gemtuzumab.Due to its CD33 binding, BL-M11D1 has specificity toward CD33 expression hematopoietic malignancies including AML.The BL-M11D1 is engineered to have an IgG wt FC receptor allowing for the mediation of innate immune effector functions toward the cancer cells. Upon antibody mediated internalization, BL-M11D1 is trafficked to cancer cell lysosomes and liberates its therapeutic payload that induced genotoxic stress activating pathways leading to cancer cell death. 

BL-M11D1 is currently being evaluated as a single agent in clinical trials enrolling patients with a variety of CD33+ hematopoietic malignancies.